Tags

Type your tag names separated by a space and hit enter

Gastro-oesophageal reflux in obese subjects: influence of overweight, weight loss and chronic gastric balloon distension.
Scand J Gastroenterol 2002; 37(11):1246-52SJ

Abstract

BACKGROUND

Gastro-oesophageal reflux is an obesity-related health risk assumed to improve after weight loss. Prolonged intragastric balloon distension might oppose this. The purpose of the study was to investigate the prevalence of gastro-oesophageal reflux in untreated obese subjects and to study the consequences of weight loss with or without intragastric balloon treatment.

METHODS

Patients participating in a randomized double-blind, sham-controlled trial received balloon or sham treatment for the first 13 weeks. Thereafter, all subjects received a balloon for the remaining year. Twenty-four-hour pH recordings were made at the start, after 13 weeks of balloon or sham treatment, after 26 and 52 weeks of balloon treatment and 13 weeks after balloon removal.

RESULTS

Group-wise, pH data of 42 untreated patients (BMI 43.4 kg/m2) were highly abnormal. On an individual level, 22 subjects (52%) had some evidence of reflux, 17 patients (40%) showed pathological total reflux times and 8 (19%) had combined total, upright and supine reflux with grade B reflux oesophagitis in only one patient. Albeit poorly, oesophageal acid exposure was related to body weight and visceral fat distribution. A reduction in acid reflux was observed in sham-treated weight-losing subjects, whereas in balloon-treated subjects supine reflux and duration of the longest reflux increased. In the second 13-week period, the initially improved pH values worsened by balloon placement in sham-treated subjects. Values in balloon-balloon-treated subjects stabilized. After 52 weeks, acid reflux levelled off at pretreatment values and further improved after balloon removal. At these times, decreased visceral fat masses correlated significantly with diminished oesophageal exposure to acid.

CONCLUSIONS

Obesity predisposed to gastro-oesophageal reflux. Body weight loss and, strikingly, visceral fat loss resulted in improved reflux parameters. Adverse effects on acid reflux by gastric balloon distension wore off over time.

Authors+Show Affiliations

Dept. of Gastroenterology and Hepatology, Academic Medical Centre, University of Amsterdam, The Netherlands. e.mathus-vliegen@amc.uva.nlNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

12465720

Citation

Mathus-Vliegen, E M H., and G N J. Tygat. "Gastro-oesophageal Reflux in Obese Subjects: Influence of Overweight, Weight Loss and Chronic Gastric Balloon Distension." Scandinavian Journal of Gastroenterology, vol. 37, no. 11, 2002, pp. 1246-52.
Mathus-Vliegen EM, Tygat GN. Gastro-oesophageal reflux in obese subjects: influence of overweight, weight loss and chronic gastric balloon distension. Scand J Gastroenterol. 2002;37(11):1246-52.
Mathus-Vliegen, E. M., & Tygat, G. N. (2002). Gastro-oesophageal reflux in obese subjects: influence of overweight, weight loss and chronic gastric balloon distension. Scandinavian Journal of Gastroenterology, 37(11), pp. 1246-52.
Mathus-Vliegen EM, Tygat GN. Gastro-oesophageal Reflux in Obese Subjects: Influence of Overweight, Weight Loss and Chronic Gastric Balloon Distension. Scand J Gastroenterol. 2002;37(11):1246-52. PubMed PMID: 12465720.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Gastro-oesophageal reflux in obese subjects: influence of overweight, weight loss and chronic gastric balloon distension. AU - Mathus-Vliegen,E M H, AU - Tygat,G N J, PY - 2002/12/6/pubmed PY - 2003/4/30/medline PY - 2002/12/6/entrez SP - 1246 EP - 52 JF - Scandinavian journal of gastroenterology JO - Scand. J. Gastroenterol. VL - 37 IS - 11 N2 - BACKGROUND: Gastro-oesophageal reflux is an obesity-related health risk assumed to improve after weight loss. Prolonged intragastric balloon distension might oppose this. The purpose of the study was to investigate the prevalence of gastro-oesophageal reflux in untreated obese subjects and to study the consequences of weight loss with or without intragastric balloon treatment. METHODS: Patients participating in a randomized double-blind, sham-controlled trial received balloon or sham treatment for the first 13 weeks. Thereafter, all subjects received a balloon for the remaining year. Twenty-four-hour pH recordings were made at the start, after 13 weeks of balloon or sham treatment, after 26 and 52 weeks of balloon treatment and 13 weeks after balloon removal. RESULTS: Group-wise, pH data of 42 untreated patients (BMI 43.4 kg/m2) were highly abnormal. On an individual level, 22 subjects (52%) had some evidence of reflux, 17 patients (40%) showed pathological total reflux times and 8 (19%) had combined total, upright and supine reflux with grade B reflux oesophagitis in only one patient. Albeit poorly, oesophageal acid exposure was related to body weight and visceral fat distribution. A reduction in acid reflux was observed in sham-treated weight-losing subjects, whereas in balloon-treated subjects supine reflux and duration of the longest reflux increased. In the second 13-week period, the initially improved pH values worsened by balloon placement in sham-treated subjects. Values in balloon-balloon-treated subjects stabilized. After 52 weeks, acid reflux levelled off at pretreatment values and further improved after balloon removal. At these times, decreased visceral fat masses correlated significantly with diminished oesophageal exposure to acid. CONCLUSIONS: Obesity predisposed to gastro-oesophageal reflux. Body weight loss and, strikingly, visceral fat loss resulted in improved reflux parameters. Adverse effects on acid reflux by gastric balloon distension wore off over time. SN - 0036-5521 UR - https://www.unboundmedicine.com/medline/citation/12465720/Gastro_oesophageal_reflux_in_obese_subjects:_influence_of_overweight_weight_loss_and_chronic_gastric_balloon_distension_ L2 - http://www.tandfonline.com/doi/full/10.1080/003655202761020498 DB - PRIME DP - Unbound Medicine ER -